BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pathology News - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pathology News
X-ORIGINAL-URL:https://www.pathologynews.com
X-WR-CALDESC:Events for Pathology News
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/London
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20251026T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20260329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20261025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20270328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20271031T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/London:20260505T160000
DTEND;TZID=Europe/London:20260505T170000
DTSTAMP:20260827T191837
CREATED:20260330T083139Z
LAST-MODIFIED:20260330T083139Z
UID:100119976-1777996800-1778000400@www.pathologynews.com
SUMMARY:Advancing Precision Medicine Through Pathology and AI-Powered CDx with Indica Labs
DESCRIPTION:0000Days00Hrs00Min00SecThe webinar starts at 8:00 PDT\, 11:00 EDT\, 16:00 BST \nLearn about Indica Labs’ ability to deliver AI-driven CDx\n\n\nSummary\n\n\n\n\nJoin Indica Labs for an exciting webinar on developing AI-powered companion diagnostics in digital pathology. In this comprehensive session\, Indica Labs will introduce its vision for transforming bench to bedside to bench workflows\, take a deep dive into our experience in AI image analysis\, and demonstrate its ability to bring diagnostic products to market. Along the way\, you’ll learn about our experience conducting early proof-of-concept studies\, advancing them to biomarker discovery\, and managing clinical trial assays.   \nDon’t miss this opportunity to hear from senior executives as well as the CEO and Founder of Indica Labs on the topic of developing AI-driven companion diagnostics.  \n\n\nLearning Objectives\n\nLearn about Indica Labs’ initiatives and strategy for developing AI-powered CDx products in digital pathology\nGain insight into Indica Labs’ strategic partnership with Leica Biosystems\nDiscover how Indica Labs can take AI-based early proof-of–concept studies all the way through the development lifecycle to become a regulatory approved CDx\nFind out about deployment options in the CE-IVDR HALO AP® platform\nUnderstand the pathway to regulatory approval for CDx co-developed with Indica Labs and options for additional strategic partnerships\n\nHALO AP® is CE-IVDR marked for in-vitro diagnostic use in Europe\, the UK\, and Switzerland. HALO AP® is For Research Use Only in the USA and is not FDA cleared for clinical diagnostic use. In addition\, HALO AP® provides built-in compliance with FDA 21 CFR Part 11\, HIPAA\, and GDPR. \nRegister Now\nPresenters\n\nSteven Hashagen \nCEO and Founder\nIndica Labs  \nSteven Hashagen is the founder and CEO of Indica Labs\, a leading digital pathology software and AI company. Prior to forming Indica Labs in 2011\, Steven held software engineering\, software architect\, and product management roles at Aperio Technologies. Through this combined experience Steven has been a pioneer in the digital pathology field for over 20 years.  \nPeter Caie\, PhD\nSr. Director\, Precision Medicine\nIndica Labs \nPeter Caie worked for 9 years as a Senior Scientist at AstraZeneca before completing his PhD from the University of Edinburgh in Cancer Pathology. He went on to run the Quantitative and Digital Pathology (QUAD) Lab at the University of St Andrews where his research focused on artificial intelligence\, cancer prognosis and diagnosis in the field of digital and molecular pathology. Currently\, Dr. Caie is a Senior Director at Indica Labs where he manages the development of commercial AI products\, including CDx assays\, designed for deployment in both the clinical and life science fields.  \nDoug Bowman (Moderator)\nVP Precision Medicine\nIndica Labs  \nDoug is responsible for Indica Labs’ Precision Medicine group that partners with pharma companies to bring new AI-powered companion diagnostics to market. His team leads the commercial development of clinical AI solutions that deploy in HALO AP® and span laboratory operations to clinical research and diagnostic use cases. His Pharma Services team\, with deep experience in quantitative image analysis services\, supports customers’ pre-clinical and clinical biomarker assays. Prior to Indica Labs\, he spent 12+ years at Takeda Pharmaceuticals where he led the tissue-based imaging capabilities to support early discovery\, translational\, and clinical programs. Doug has a BSE in biomedical and electrical engineering from Duke University. 
URL:https://www.pathologynews.com/event/advancing-precision-medicine-through-pathology-and-ai-powered-cdx-with-indica-labs/
LOCATION:Online
CATEGORIES:Live Online Webinar
ATTACH;FMTTYPE=image/jpeg:https://www.pathologynews.com/wp-content/uploads/2026/03/Advancing-Precision-Medicine-Through-Pathology-and-AI-Powered-CDx-with-Indica-Labs.jpg
END:VEVENT
END:VCALENDAR